Advertisement


Matthew A. Powell, MD, and Don S. Dizon, MD, on Uterine or Ovarian Cancer: Paclitaxel Plus Carboplatin vs Ifosfamide in Chemotherapy-Naive Patients

2019 ASCO Annual Meeting

Advertisement

Don S. Dizon, MD, of the Lifespan Cancer Institute, and Matthew A. Powell, MD, of Washington University School of Medicine, discuss phase III findings on paclitaxel plus carboplatin vs paclitaxel plus ifosfamide in chemotherapy-naive patients with stages I to IV, persistent or recurrent carcinosarcoma of the uterus or ovaries (Abstract 5500).

 



Related Videos

Multiple Myeloma

Francesca Gay, MD, on Multiple Myeloma: Carfilzomib/Lenalidomide/Dexamethasone With or Without Transplantation

Francesca Gay, MD, of GIMEMA, European Myeloma Network, discusses the results of the FORTE trial on the efficacy of carfilzomib/lenalidomide/dexamethasone with or without autologous stem cell transplantation according to risk status in newly diagnosed disease (Abstract 8002).

 

Solid Tumors

Hani M. Babiker, MD, on Tumor Treating Fields: A Different Approach to Therapy

Hani M. Babiker, MD, of the The University of Arizona, discusses an emerging treatment that inhibits the mitotic spindle and disrupts tumor cell growth. The method has been approved by the FDA to treat some cancers and data show improved progression-free and overall survival (Abstracts 2055, 8551, e14658, e14668, e15653, e20069, e15766).

 

Breast Cancer

Yeon Hee Park, MD, on Metastatic Breast Cancer: Palbociclib, Exemestane, and GnRH Agonist

Yeon Hee Park, MD, of the Samsung Medical Center, discusses phase II study findings that showed exemestane plus palbociclib with ovarian suppression improved progression-free survival compared with capecitabine in premenopausal estrogen receptor–positive metastatic breast cancer (Abstract 1007).

Breast Cancer

Patricia A. Ganz, MD, on Breast Cancer: Whole- vs Partial-Breast Irradiation

Patricia A. Ganz, MD, of NRG Oncology and Jonsson Comprehensive Cancer Center at UCLA, discusses the NRG/NSABP phase III findings, which showed that partial-breast irradiation was more convenient and resulted in less fatigue but slightly poorer cosmesis at 36 months in patients who did not receive chemotherapy (Abstract 508).

Colorectal Cancer

Åsmund A. Fretland, MD, on Colorectal Cancer Liver Metastases: Laparoscopic vs Open Resection

Åsmund A. Fretland, MD, of Oslo University Hospital, discusses clinical trial findings on survival outcomes after laparoscopic vs open resection for colorectal liver metastases. The study he conducted with his team showed that the laparoscopic procedure did not jeopardize long-term survival (Abstract LBA3516).

Advertisement

Advertisement




Advertisement